Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Anticancer composition containing neovascularization inhibitor and bortezomib

A technology of bortezomib and neovascularization, which is applied in the direction of active ingredients of boron compounds, drug combinations, non-active ingredients of polymer compounds, etc., and can solve problems such as toxic reactions, inability to effectively kill tumor cells, and burst release

Inactive Publication Date: 2008-11-12
济南基福医药科技有限公司
View PDF16 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] However, the sustained-release excipients used in the existing above-mentioned and other pharmaceutical preparations more or less cause sudden release or uneven release of the drug when the drug is released.
Some drugs are released too slowly, which is not enough to obtain effective drug concentration in the local area, so they cannot effectively kill tumor cells; some release drugs too fast, often causing burst release, which is likely to cause systemic toxic reactions like conventional injections

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Anticancer composition containing neovascularization inhibitor and bortezomib
  • Anticancer composition containing neovascularization inhibitor and bortezomib
  • Anticancer composition containing neovascularization inhibitor and bortezomib

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0108] Put 90, 90 and 80mg p(BHET-EOP / TC), BHET-EOP: TC is 80:20) copolymer into three containers of A, B and C respectively, and then add 100 ml of dichloromethane to each , after dissolving and mixing, add 10mg erlotinib, 10mg bortezomib, 10mg erlotinib and 10mg bortezomib respectively, reshake and prepare 10% erlotinib, 10% boron Tezomib, and microspheres for injection with 10% erlotinib and 10% bortezomib. Then suspend the microspheres in physiological saline containing 15% mannitol to prepare the corresponding suspension-type sustained-release injection. The release time of the slow-release injection in physiological saline in vitro is 40-50 days, and the release time in mice subcutaneously is more than 50 days.

Embodiment 2

[0110] The method step of being processed into slow-release injection is identical with embodiment 1, but difference is that used auxiliary material is the p(BHET-EOP / TC) of 50: 50, containing anticancer active ingredient and weight percent thereof are:

[0111] (1) 5-30% erlotinib or gefitinib;

[0112] (2) 5-30% bortezomib; or

[0113] (3) Combination of 5-30% erlotinib or gefitinib and 5-30% bortezomib.

Embodiment 3

[0115] Put 70 mg of p(LAEG-EOP) with a peak molecular weight of 10,000-25,000 into three containers of A, B, and C, respectively, and then add 100 ml of dichloromethane to each, dissolve and mix well, and pour into the three containers respectively Add 30mg gefitinib, 30mg bortezomib, 15mg gefitinib and 15mg bortezomib, re-shake and use spray drying method to prepare 30% gefitinib, 30% bortezomib, 15% gefitinib Microspheres for injection of tinib and 15% bortezomib. The dried microspheres are suspended in physiological saline containing 1.5% sodium carboxymethylcellulose to prepare the corresponding suspension-type sustained-release injection. The drug release time of the sustained release injection in physiological saline in vitro is 50-65 days, and the drug release time in mice subcutaneous is about 60 days.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Molecular weightaaaaaaaaaa
Login to View More

Abstract

The invention provides a sustained-release injection which is an anti-tumor composite containing agiogenesis inhibitors and bortezomib. The sustained-release injection comprises a sustained-release microsphere and a solution medium, wherein the sustained-release microsphere comprises effective anti-tumor ingredient and sustained-release excipient, the solution medium is a common solution medium or a special solution medium containing a suspending drug. The suspending drug has the viscosity between 100cp and 3000cp (under twenty centi degrees to thirty centi degrees) and is selected from sodium carboxymethylcellulose and others; the effective anti-tumor ingredient comprises the agiogenesis inhibitors and / or the combination thereof; the sustained-release excipient is selected from polyphosphonate copolymer like p(LAEG-EOP)or p(DAPG-EOP), PLA, polyphosphonate with PLA, polifeprosan, copolymer of dual fatty acid and sebacic acid, the polymer or blending polymer of ( erucic acid dipolymer-sebacic acid) or poly(boletic acid-sebacic acid); the anti-tumor composite can also be prepared to be a sustained-release implant which can maintain the effective concentration of drug over forty days for intratumor or tumor circumference injection or placement, can also reduce general reaction obviously and enhance the treatment effect of non-operative therapeutics such as chemotherapy and radiotherapy.

Description

(1) Technical field [0001] The invention relates to an anticancer composition containing angiogenesis inhibitor and bortezomib, which belongs to the technical field of medicines. Specifically, the invention relates to a sustained-release preparation capable of stably releasing angiogenesis inhibitors and bortezomib locally in solid tumors, mainly sustained-release implants and sustained-release injections, which can prolong the drug release time and can Increased drug sensitivity. (2) Background technology [0002] The latest data show that in 2006, 3 million people died of cancer in my country. The incidence of cancer is increasing year by year and tends to be younger. Statistics show that in less than 20 years, the incidence of cancer in my country has increased by 69%, and the mortality rate has increased by 29.4%. According to the latest statistics from the World Health Organization, the global cancer incidence rate will increase by 50% by 2020, and the number of patie...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K45/00A61K31/69A61K47/40A61K9/00A61K9/08A61P35/00
Inventor 毛海婷孔庆新王明华
Owner 济南基福医药科技有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com